Patents by Inventor Stefan Irion

Stefan Irion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF GENERATING AND ISOLATING MIDBRAIN DOPAMINE NEURONS
    Publication number: 20220177835
    Abstract: The present disclosure provides methods for generating midbrain dopamine neurons (mDAs) and precursors thereof, mDAs and precursors thereof generated by such methods and compositions comprising such cells, and uses thereof for preventing and/or treating neurological disorders. The present disclosure further provides methods of isolating mDAs and precursors thereof from a cell population using novel surface markers.
    Type: Application
    Filed: February 25, 2022
    Publication date: June 9, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Taewan Kim, Stefan Irion, So Yeon Koo
  • Vector for targeting the human Rosa26 gene
    Patent number: 11078494
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: August 3, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS
    Publication number: 20210123018
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 29, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • Methods of in vitro differentiation of midbrain dopamine (MPA) neurons
    Patent number: 10858625
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 8, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • STEM CELL GENE TARGETING
    Publication number: 20200071719
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Application
    Filed: October 25, 2019
    Publication date: March 5, 2020
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS
    Publication number: 20180094242
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into midbrain dopamine neurons, and precursors thereof, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative disorders.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lorenz Studer, Stefan Irion, Mark Tomishima, Sonja Kriks
  • STEM CELL GENE TARGETING
    Publication number: 20170298384
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Application
    Filed: October 21, 2016
    Publication date: October 19, 2017
    Inventors: Gordon M. Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • Stem cell gene targeting
    Patent number: 9481896
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: November 1, 2016
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • STEM CELL GENE TARGETING
    Publication number: 20160017371
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Application
    Filed: May 20, 2015
    Publication date: January 21, 2016
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans J. Fehling
  • Targeting the Rosa26 gene in human embryonic stem cells
    Patent number: 9062122
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: June 23, 2015
    Assignee: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans Joerg Fehling
  • INTEGRATION-FREE HUMAN INDUCED PLURIPOTENT STEM CELLS FROM BLOOD
    Publication number: 20110281281
    Abstract: Provided herein are methods for generating human induced pluripotent stem cells free from genomic integration of exogenous transgenes by transfecting into nucleated blood cells one or more DNA expression vectors (e.g., plasmid vectors) that do not contain a mammalian origin of replication, and encode and permit expression of one or more reprogramming factors (e.g., Oct4, Sox2, Klf4, and c-Myc). Also provided herein are the integration-free human induced pluripotent stem cells obtained by the methods described herein.
    Type: Application
    Filed: May 12, 2010
    Publication date: November 17, 2011
    Applicant: iPierian, Inc.
    Inventor: Stefan Irion
  • Integration-free human induced pluripotent stem cells from blood
    Patent number: 8048675
    Abstract: Provided herein are methods for generating human induced pluripotent stem cells free from genomic integration of exogenous transgenes by transfecting into nucleated blood cells one or more DNA expression vectors (e.g., plasmid vectors) that do not contain a mammalian origin of replication, and encode and permit expression of one or more reprogramming factors (e.g., Oct4, Sox2, Klf4, and c-Myc). Also provided herein are the integration-free human induced pluripotent stem cells obtained by the methods described herein.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: November 1, 2011
    Assignee: iPierian, Inc.
    Inventor: Stefan Irion
  • CO-CULTURE COMPOSITIONS AND METHODS
    Publication number: 20110262956
    Abstract: Co-culture compositions and methods are described for identifying agents that modulate a cellular phenotype, particularly of neurons or pancreatic beta cells are provided herein, where the methods include co-culturing differentiated cells, wherein at least one of the cell-types are derived from human induced pluripotent stem cells from a subject having or predisposed to a neurodegenerative or metabolic disorder. Co-culture compositions of differentiated cells from two different human subjects are also described.
    Type: Application
    Filed: October 7, 2009
    Publication date: October 27, 2011
    Inventors: Guillermo Munoz Elias, Ashkan Javaherian, Stefan Irion
  • STEM CELL GENE TARGETING
    Publication number: 20100011455
    Abstract: The invention provides a method for generating a transgenic eukaryotic cell population having a modified human Rosa26 locus, which method includes introducing a functional DNA sequence into the human Rosa26 locus of starting eukaryotic cells. Also provided are targeting vectors useful in the method, as well as a cell population and a transgenic non-human animal comprising a modified human Rosa26 locus. Finally, the invention provides an isolated DNA sequence corresponding to the human Rosa26 locus.
    Type: Application
    Filed: January 18, 2008
    Publication date: January 14, 2010
    Applicant: Mount Sinai School of Medicine of New York Univers
    Inventors: Gordon Keller, Stefan Irion, Herve Luche, Paul Gadue, Hans Joerg Fehling